Skip to main content
Log in

Surrogate endpoints: A basis for a rational approach

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

In clinical trials, the clinical endpoint is often replaced by an intermediate endpoint, known in some instances as a “surrogate” endpoint. The reasons for the substitution are often both practical and financial. At present, no theoretical basis or practical guidelines exist to help in the choice of surrogate endpoints.

An approach is proposed here, based on three provisos which can be verified using one of a series of equations, if sufficient data on the pathophysiology and epidemiology of the disease are available. It is shown that even a strong statistical correlation is not a sufficient criterion for the definition of a surrogate endpoint.

It is apparent that results obtained with the commonly used “surrogate” endpoints should be cautiously considered and that the assessment of treatments should, when possible, be based on clinical rather than intermediate endpoints.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Friedman L, Furberg CD, DeMets DL (1984) Fundamentals of clinical trials, 2nd edn. PSG Publishing, Littleton

    Google Scholar 

  2. Moleur P, Boissel JP (1987) Definition of a surrogate endpoint. Controlled Clinical Trials 8: 304

    Google Scholar 

  3. Herson J (1989) The use of surrogate endpoints in clinical trials (an introduction to a series of four papers). Stat Med 8: 403–404

    Google Scholar 

  4. Ellenberg SS, Hamilton JM (1989) Surrogate endpoints in clinical trials: cancer. Stat Med 8: 405–413

    CAS  PubMed  Google Scholar 

  5. Wittes J, Lakatos L, Probstfield J (1989) Surrogate endpoints in clinical trials: cardiovascular diseases. Stat Med 8: 415–425

    CAS  PubMed  Google Scholar 

  6. Hillis A, Seigel D (1989) Surrogate endpoints in clinical trials: ophthalmologic disorders. Stat Med 8: 427–430

    CAS  PubMed  Google Scholar 

  7. Ruskin JN (1989) Editorial: the Cardiac Arrhythmia Suppression Trial. New Engl J Med 321: 386–388

    CAS  PubMed  Google Scholar 

  8. Winkle RA (1980) Detection of patients at high risk for sudden death: the role of electrocardiographic monitoring. In: Kulbertus HE, Wellens HJJ (eds) Sudden death. Martinus Nijhof, The Hague

    Google Scholar 

  9. The CAST investigators (1989) Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New Engl J Med 321: 406–412

    Google Scholar 

  10. Kannel WB, Gordon T, Schwartz MJ (1971) Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study. Am J Cardiol 27: 335–346

    Article  CAS  PubMed  Google Scholar 

  11. Pooling Project Research Group (1978) Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the Pooling Project. J Chron Dis 31: 201–306

    Google Scholar 

  12. MacMahon S, Petro R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J (1990) Blood pressure, stroke, and coronary heart disease. Part 1. prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335: 765–774

    Article  CAS  PubMed  Google Scholar 

  13. Boissel JP, Gueyffier F (1990) High blood pressure and clinical events linked with atherosclerosis. In: Atkinson J, Capdeville C, Zannad F (eds) Coronary and cerebrovascular effects of antihypertensive drugs. Transmedico Europe Ltd, UK, p 240–252

    Google Scholar 

  14. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH (1990) Blood pressure, stroke, and coronary heart disease. Part 2. short term reductions in blood pressure: overview of randomized drug trials in epidemiological context. Lancet 335: 827–838

    CAS  PubMed  Google Scholar 

  15. Okamoto K, Yamori Y, Nagaoka A (1974) Establishment of the stroke-prone spontaneously hypertensive rat (SHR). Circ Res 34: 1143–1153

    Google Scholar 

  16. Lievre M, Leizorovicz A, Boissel JP (1991) Critères intermé diaires et critères de substitution dans le développement des antiarytbmiques. Arch Mal Coeur 84: 27–33

    PubMed  Google Scholar 

  17. Hine LK, Laird NM, Hewitt P, Chalmers TC (1989) Meta analysis of empirical antiarrhythmic therapy after myocardial infarction. J Am Med Assoc 262: 3037–3040

    Article  CAS  Google Scholar 

  18. Slater W, Lampert S, Podrid J, Lown B (1988) Clinical predictors of arrhythmia worsening by antiarrhythmic drugs. Am J Cardiol 61: 349–353

    Article  CAS  PubMed  Google Scholar 

  19. Prentice RL (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8: 431–440

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boissel, J.P., Collet, J.P., Moleur, P. et al. Surrogate endpoints: A basis for a rational approach. Eur J Clin Pharmacol 43, 235–244 (1992). https://doi.org/10.1007/BF02333016

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02333016

Key words

Navigation